Open Biosystems ( reports that three research institutions joined its Open Access RNAi Program. Baylor College of Medicine, University of Minnesota, and The Mayo Clinic purchased access to the company’s shRNAmir and shRNA technologies.
“Lentiviral shRNAmir technology from Open Biosystems will enable our researchers to harness the power of RNAi in assays and cell lines, previously limited by conventional siRNA technology, through lentiviral transduction and stable vector-based selection,” notes Zhou Songyang, associate professor, biochemistry and molecular biology at Baylor.

Previous articleVentana Acquires Spring BioScience for $28.9M
Next articleAradigm and CyDex Combine Expertise to Tackle Asthma and COPD